6 completed, 2 recruiting, 1 terminated, 1 unknown. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Unknown 1 |
Follow B-cell Lymphomas: new trials by email Literature Review of B-cell Lymphomas trials Research Report on B-cell Lymphomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas JV-213, Leukapheresis - Lymphomas, B-cell Lymphomas | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 33 | 2023-04-14 | 2026-07-29 |
| Long-term Registry of Patients Treated With Loncastuximab Tesirine B-Cell Lymphomas | Withdrawn | ADC Therapeutics S.A. | 2022-06-30 | 2022-06-22 | ||
| Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas DTRMWXHS-12 - Chronic Lymphocytic Leukemia, B-cell Lymphomas | Phase 1 | Completed | Zhejiang DTRM Biopharma | 13 | 2016-09-01 | 2020-04-14 |
| A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas HLX01 - B-cell Lymphomas | Phase 1 | Completed | Shanghai Henlius Biotech | 12 | 2014-05-04 | 2022-05-09 |
| Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas Anti-CD19 CAR T cells - B-cell Lymphomas | Phase 1 / Phase 2 | Unknown | Peking University | 20 | 2014-01-01 | 2014-10-20 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Ublituximab, Lenalidomide - Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | TG Therapeutics, Inc. | 10 | 2012-11-21 | 2022-05-11 |
| Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients Ofatumumab - B-Cell Lymphomas | Phase 2 | Completed | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 33 | 2012-04-04 | 2021-05-26 |
| Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) Oxaliplatin, Prednisolone - B-cell Lymphomas | Phase 2 | Completed | Dong-A University Hospital | 42 | 2009-10-01 | 2014-11-04 |
| Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen B-Cell Lymphomas | Completed | Fondazione Italiana Linfomi - ETS | 1927 | 2009-05-01 | 2011-11-23 | |
| High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement High-dose sequential chemotherapy and autologous transplant - B-cell Lymphomas | Phase 2 | Completed | Andrés José Maria Ferreri | 40 | 2007-01-01 | 2024-12-10 |
Lymphoma, B-Cell (11) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Recurrence (2) · Burkitt Lymphoma (1) · Disease (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Meningeal Carcinomatosis (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma (8) · Lymphoma, Non-Hodgkin (8) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Chronic Disease (2) · Hematologic Diseases (2) · Leukemia (2)
Leukapheresis (2) · Cyclophosphamide (1) · DTRMWXHS-12 (1) · Lenalidomide (1) · Oxaliplatin (1) · Prednisolone (1) · Transplantation, Autologous (1) · fludarabine (1) · gemcitabine-oxaliplatin regimen (1) · glofitamab (1) · obinutuzumab (1) · ofatumumab (1) · ublituximab (1)
ADC Therapeutics S.A. (1) · Andrés José Maria Ferreri (1) · Dong-A University Hospital (1) · Fondazione Italiana Linfomi - ETS (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Peking University (1) · Shanghai Henlius Biotech (1) · TG Therapeutics, Inc. (1) · Zhejiang DTRM Biopharma (1)
United States (4) · China (2) · Italy (2) · Brazil (1) · South Korea (1) · Spain (1)
Cheolwon Suh, M.D., Ph.D. (1) · Jeremy Abramson, MD, MMSc (1) · Jun Zhu, MD (1) · Maria Dolores Caballero, MD (1) · Massimo Federico, MD (1) · Sattva Neelapu, MD (1) · Stefano Luminari, MD (1) · Sung Yong Oh, M.D., Ph.D. (1) · Wei He, Ph.D. (1)